Using monoamine oxidase type B inhibitors in Parkinson's disease

British Medical Journal

Volumn 329, Issue 7466, 2004, Pages 581-582

  Ben Shlomo, Yoav ^a   Bhatia, Kailash ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPARKINSON AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; MONOAMINE OXIDASE INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDITORIAL; HUMAN; MONOTHERAPY; MORTALITY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; NOTE; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 4544241362     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7466.581     Document Type: Editorial

References (10)

1. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
2. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593-6.
3. Anonymous. MAO-B inhibitors for the treatment of Parkinson's disease. Movement Disord 2002;17(suppl 4):s38-s44.
4. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98.
5. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43.
6. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
7. Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, et al. Investigation by Parkinson's disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998;316:1191-6.
8. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25.
9. Lees AJ, Katzenschlager R, Head J, Ben Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo Parkinson's disease: a randomized trial. Neurology 2001;57:1687-94.
10. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology. J Neurol Neurosurg Psychiatry 1995;58:293-9.